Tracks outcomes of a pediatric-style treatment for young adults with acute leukemia
Observes how young adults with Philadelphia-negative acute lymphoblastic leukemia fare on first-line pediatric-style treatment.
Plain-language title generated from the registry record
Registry title: RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL
Key facts
- Where
- CABA and Paraná, ArgentinaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adolescents and young adults newly diagnosed with Philadelphia-negative acute lymphoblastic leukemia (ALL) who have not been treated yet.
- Age
- 18 to 40 years
- Sex
- Women and men can join.
- Disease stage
- Newly diagnosed Philadelphia-negative acute lymphoblastic leukemia (ALL), with no previous treatment.
- Earlier treatment
- No previous treatment for this leukemia.
- Biomarker or test result
- Philadelphia-negative (Ph-negative) ALL. Ph-positive ALL cannot join.
Main reasons for not taking part
- ALL with mature B phenotype (sIg +) or its typical gene changes
- Ph-positive ALL, or acute leukemia of ambiguous lineage
- Past heart disease that rules out the use of anthracyclines
- Severe liver, lung, kidney or nerve problems not caused by ALL
- Uncontrolled infection with HIV, HTLV-1, HBV or HCV
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT05127148, who can take part
Where in Argentina
- FUNDALEUCABA, ArgentinaContact: Luciana Ferrari, Dr.Taking people
- Instituto Privado de Hematologia y HemoterapiaParaná, ArgentinaContact: Pedro Negri Aranguren, Dr.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Grupo Argentino de Tratamiento de la Leucemia Aguda
- Trial code
- NCT05127148
- Record updated
- 9 January 2024
- Original description
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of adolescent and young patients with ph-negative acute lymphoblastic leukemia with first-line pediatric-like protocol in Argentina.Read full original descriptionShow less
Real-world Evidence of First-line Treatment With Pediatric-like Protocol for Adolescents and Young Adults Patients Diagnosed With Philadelphia-negative Acute Lymphoblastic Leukemia
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of adolescent and young patients with ph-negative acute lymphoblastic leukemia with first-line pediatric-like protocol in Argentina.
Inclusion: Signature of the form consent for participation in the study; Ph-negative ALL diagnosis without previous treatment.
Exclusion: Patients with a history of coronary, valvular or hypertensive heart disease, that contraindicate the use of anthracyclines; Patients with severe chronic respiratory failure; Renal failure and / or creatininemia> 2 mg / dl not related to ALL; Serious neurological disorders, not related to leukemic disease; General condition affected (grades 3 and 4), not attributable to ALL; Uncontrolled infection by HIV, HTLV-1, HBV, HCV; Patients with chronic liver disease in the activity phase and / or Bilirubin> 2 mg / dl and / or transaminases 5 times the normal limit, not related to ALL; ALL with mature B phenotype (sIg +) or with the cytogenetic alterations characteristic of ALL mature B (t (8,14), t (2, 8), t (8, 22)); Ph-positive ALL; Acute leukemias of ambiguous lineage (undifferentiated or mixed phenotype); Patient not a candidate for treatment based on the criteria of the treating physician; Pregnant women will have to be evaluated by a multidisciplinary team and an ethics committee.